Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Development of an HIV vaccine presents a formidable challenge. One of the unresolved, yet central issues is the importance of HIV variability. Here we argue that even with the recent focus on the induction of T cell-mediated immunity, HIV vaccines should match the local circulating HIV clades. Whether used alone or in a combination with vaccines eliciting HIV-neutralizing antibodies, efforts must be made to develop a T cell vaccine that stimulates a broad and long-lasting response.


Journal article



Publication Date





1918 - 1921


AIDS Vaccines, Amino Acid Sequence, Animals, Antigen Presentation, Antigenic Variation, Clinical Trials, Phase I as Topic, Epitopes, HIV, HIV Antibodies, HIV Antigens, HIV Infections, HLA Antigens, Humans, Immunity, Cellular, Immunologic Memory, Interleukin-2, Kenya, Macaca, Mice, Neutralization Tests, Structure-Activity Relationship, T-Lymphocytes, Cytotoxic, Vaccines, DNA, Vaccines, Synthetic